FDA approves AstraZeneca’s baxdrostat for certain patients with hypertension
One of the key products underpinning AstraZeneca’s goal of hitting $80 billion in revenue by 2030 has been approved by the FDA, the drugmaker said Monday. The blood ...
May 18, 2026 06:01 AM EDT PharmaFDA+ AstraZeneca's blood pressure pill approved, but competition could be around the corner Elizabeth Cairns Senior biopharma journalist One of the key products underpinning AstraZeneca’s goal of hitting $80 billion in revenue by 2030 has been approved by the FDA … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that